|Videos|November 10, 2017

What Are the Major Challenges Associated with Diagnosing CDI?

Ferric Fang, MD, explains the major challenges associated with diagnosing Clostridium difficile infection.

Ferric Fang, MD, professor, Lab Medicine/S.D., at the University of Washington, explains the major challenges associated with diagnosing Clostridium difficile infection.

Interview Transcript (modified slightly for readability):

“What are the major challenges to diagnosing [Clostridium difficile infection] CDI? The difficulty is not really in detecting toxigenic C. difficile, but in terms of its interpretation, because this is an organism that can cause asymptomatic colonization, self-limited disease, moderately severe disease, or life-threatening disease, and the diagnostic test can’t really tell you whether the patient has asymptomatic colonization or serious disease. So, this creates a lot of uncertainty about to interpret a test.

And one way to work around this is to look at the presence of the toxin, instead of the presence of the organism. And the presence of the toxin tends to correlate with a higher organism burden, but unfortunately, it doesn’t fall out neatly that the presence of the toxin tells you if you have disease. You can actually have toxin present and have colonization, or you can fail to detect toxin and have life-threatening disease. And so, there’s still this piece of the clinical assessment that is indispensable; it has to be the context in which the laboratory test is interpreted.”


Related to this article

Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
LMN-201 Reduces C difficile Recurrence
In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.